Listen to Understand

We investigate the world of Biochemistry and Tech-driven Health Care

How Tag.bio Makes It Easier to Interrogate Your Data

May 10, 2021

Moneyball Medicine®

The discoveries medical researchers and drug developers can make are constrained by the kinds of questions they can ask of their data. Unfortunately, when it comes to clinical trial data, or gene expression data, or population health data, it feels like you need a PhD in computer science just to know which questions are "askable" and how to frame them. This week, Harry talks with the founders of a startup working to solve that problem.

47 min 03 sec

Ramy Farid on the Power of Computation in Drug Discovery


Moneyball Medicine®

Harry interviews Ramy Farid, president and CEO of Schrödinger Pharmaceuticals, about the company’s success using chemical simulation software to help drug makers zero in on promising drug candidates—and about its recent IPO, which brought in more than twice as much cash as the company expected.

28 min 50 sec

Illumina's Phil Febbo on Sequencing, Coronavirus and Viral Outbreaks


Moneyball Medicine®

As the Wuhan coronavirus outbreak spreads in Asia, Harry speaks with Phil Febbo, the chief medical officer of Illumina, one of the world’s largest makers of equipment for high-throughput DNA sequencing. Febbo highlights sequencing’s emerging contribution to the understanding and treatment of infectious disease.

28 min 36 sec

Daniella Gilboa on How Deep Learning Can Revolutionize IVF


Moneyball Medicine®

Daniella Gilboa is an embryologist in Israel working to bring the power of AI and machine learning to the embryo selection phase of IVF treatment. She explains how her new startup aims to automate this error-ridden process, raising efficiency and lowering the overall cost of IVF.

30 min 55 sec

Tom Davenport on the Analytics Gap in Healthcare


Moneyball Medicine®

Harry’s guest this week is Tom Davenport, who argues that the healthcare industry is way behind in its use of big-data analytics software to make smarter decisions about business and patient care. “This is a period of lots of opportunity to use new technologies to change healthcare, and God knows we need it, from a value-for-expense standpoint,” Davenport tells Harry. “But we’re not really at the point, at least on the clinical side yet, where we see a lot of direct applications. We’re still in the age of compiling transaction data. We haven’t used it much yet to make decisions and take actions.”

31 min 53 sec

Milind Kamkolkar on Seeing the Forest and the Trees at Cellarity


Moneyball Medicine®

Harry welcomes Milind Kamkolkar back to the program. The former Sanofi exec is now the chief data and digital officer at Cellarity, a Flagship Pioneering-backed therapeutics startup working to model cell behavior computationally in order to identify new drug targets and therapies.

38 min 21 sec

Alan Copperman on How Data is Transforming Reproductive Medicine


Moneyball Medicine®

This week Harry welcomes a guest who could be considered a "poster child" for the movement to incorporate more data into clinical practice: Dr. Alan Copperman, a New York-based specialist in reproductive medicine. He says the data generated by genetic screening of fertilized embryos is rapidly and dramatically improving outcomes for couples who want children.

27 min 14 sec

Gini Deshpande of NuMedii on Augmented Intelligence for Drug Discovery


Moneyball Medicine®

This week Harry talks with Gini Deshpande, the co-founder and CEO of San Mateo, CA-based NuMedii, a company making judicious use of big data and AI to speed up drug discovery.

28 min 33 sec

Chris Boone of Pfizer on Being a Data Hippie


Moneyball Medicine®

This week Harry talks with Chris Boone, a leader of Pfizer's effort to use new types of real-world data on patients—from insurance claims to lab tests to molecular profiles to data from wearable health sensor—to speed up drug discovery, development, and testing.

37 min 21 sec

Kevin Tabb of Beth Israel Lahey Health on How to Get Ahead of Change in Healthcare


Moneyball Medicine®

Harry talks with the CEO and president of Beth Israel Lahey Health, the product of Lahey Health's merger this spring with Beth Israel Deaconess Medical Center and several other hospitals in the Boston region. How does Dr. Tabb manage change inside a growing organization that—by his own admission—has to build and implement new tools, processes and the actionable data it needs to evolve beyond the fee-for-service era.

35 min 39 sec

Peter Coffee and Salesforce's Vision for the Platformization of Healthcare


Moneyball Medicine®

Harry talks this week with Salesforce's vice president of strategic research, Peter Coffee. The computer-industry veteran and former tech columist says that in the era of 1) outcomes-based payments for medical care, 2) an aging patient base, and 3) ubiquitous sensors and continuous data collection, there's a huge opportunity—and financial incentive—for healthcare providers to employ technology platforms that improve the client experience.

45 min 25 sec

Rhoda Au on Digital Biomarkers and Precision Brain Health


Moneyball Medicine®

Harry speaks with Boston University’s Rhoda Au, who believes that algorithms parsing new kinds of digital data about individual patients could find warning signs of diseases like dementia while they’re still preventable—leading to a new era in which precision medicine is gradually replaced by “precision health.”

40 min 03 sec

Kathryn Teng on Unlocking the Puzzle of Population Health


Moneyball Medicine®

Harry has a heart-to-heart conversation with Dr. Kathryn Teng, who’s working to use data to implement an access- and experience-based population health model at MetroHealth, the public health system for Cuyahoga County, Ohio.

39 min 59 sec

Alán Aspuru-Guzik and the Revolution in Molecular Design


Moneyball Medicine®

Harry gets an update on the merger of AI, robotics, and high-throughput chemistry in the new "self-driving laboratory" from University of Toronto theoretical chemist Alán Aspuru-Guzik.

31 min 20 sec

Jennifer Carter and the Power of Individualized Cancer Care


Moneyball Medicine®

This week Harry learns about the power of individualized molecular diagnostics for cancer patients from N-of-One founder Jennifer Levin Carter.

42 min 49 sec

Mark Boguski on Antidotes to Overspecialization in Medicine


Moneyball Medicine®

Dr. Mark Boguski argues in this week's episode that diagnostic management teams consisting of physicians from diverse specialties, including genetics and genomics, can integrate data from different specialties and improve patient care.

38 min 15 sec

Sandy Aronson on AI and Gene-based Personalized Medicine (AI World Special Series Part 2)


Moneyball Medicine®

Sandy Aronson from Partners HealthCare Personalized Medicine argues that "algorithm-enhanced care" is helping physicians make better decisions.

42 min 17 sec

Aalpen Patel and Using AI to Reduce Time-to-Diagnosis (AI World Special Series Part 1)


Moneyball Medicine®

Harry talks wth Geisinger's Dr. Aalpen Patel about machine-learning algorithms that can help radiologists read CT scans and speed up diagnosis of urgent conditions.

35 min 03 sec

Massimo Buscema on AI and What We Can and Can't See in the Human Body


Moneyball Medicine®

Harry's guest in this episode is Massimo Buscema, director of the Semeion Research Center in Rome, Italy, and a full professor at the University of Colorado at Denver. Buscema researches and consults internationally on the theory and applications of AI, artificial neural networks, and evolutionary algorithms. The conversation focuses on AI and its applications in healthcare, and how it can enhance what we can see and uncover what we cannot.

37 min 08 sec

Barrett Rollins and the DNA-driven Transformation of Oncology


Moneyball Medicine®

Harry's guest for this episode is Dr. Barrett Rollins, the chief scientific officer and faculty dean for academic affairs at Boston's Dana Farber Cancer Institute and the Linde Family Professor of Medicine at Harvard Medical School. Harry and Dr. Rollins dig into how large-scale DNA analysis can one day put much more usable information into the hands of oncologists, and how that data affects individual patients, the practice of medicine, and new therapies under development.

30 min 35 sec

Joel Dudley and What Happens When You Let Data—Not Hypotheses—Drive Discovery


Moneyball Medicine®

Harry's guest this week is Dr. Joel Dudley from the Icahn School of Medicine at Mount Sinai, where he serves as executive vice president of precision health, associate professor of genetics and genomic sciences, and founding director of the Institute for Next Generation Healthcare. Dr. Dudley explains how his group is utilizing data to uncover health problems that can't be detected through normal methods, as well as his groundbreaking paper on the link between Alzheimer's disease and herpes.

29 min 00 sec